<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND
EXCHANGE ACT OF 1934
For The Quarterly Period Ended June 30, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
AND EXCHANGE ACT OF 1934
Commission File Number: 0-19700
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 33-0266089
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
9373 Towne Centre Drive, San Diego, California 92121
(Address of principal executive offices) (Zip code)
(619) 552-2200
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former
fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
<TABLE>
<CAPTION>
Class Outstanding at June 30,1997
----- ---------------------------
<S> <C>
Common Stock, $.001 par value 32,088,896
</TABLE>
<PAGE> 2
Item 2. CHANGES IN SECURITIES.
(c)On May 9, 1997 the Company issued to the Medical Research Council ("MRC") a
warrant to purchase 20,000 shares of the Company's common stock in consideration
for entering into an amendment to a License Agreement between the Company and
the MRC. The warrant carries an exercise price of $11.375 per share and a ten
year exercise period. The issuance of the warrant was exempted from registration
with the Securities and Exchange Commission in accordance with Section 4(2) of
the Securities Act of 1933, as amended.
<PAGE> 3
AMYLIN PHARMACEUTICALS, INC.
June 30, 1997
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.
Amylin Pharmaceuticals, Inc.
Date: November 6, 1997 By: /s/ Marjorie T. Sennett
-------------------------------
Marjorie T. Sennett
Senior Vice President and
Chief Financial Officer
(on behalf of the registrant
and as the registrant's
principal financial officer)
